We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+7.98%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$6.25B
AUM Growth
-$1.7B
Cap. Flow
-$2.08B
Cap. Flow %
-33.31%
Top 10 Hldgs %
54.24%
Holding
331
New
77
Increased
88
Reduced
65
Closed
73

Top Buys

Rank Stock Value
1
FIVN icon
FIVE9
FIVN
+$41.6M
2
NARI
Inari Medical, Inc. Common Stock
NARI
+$39M
3
DPZ icon
Domino's
DPZ
+$33.2M
4
INCY icon
Incyte
INCY
+$27.6M
5
HUM icon
Humana
HUM
+$26.5M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$109M
2
EXAS
Exact Sciences
EXAS
+$59.2M
3
SNY icon
Sanofi
SNY
+$49.7M
4
KDP icon
Keurig Dr Pepper
KDP
+$49.6M
5
GSK icon
GSK
GSK
+$39.9M

Sector Composition

Rank Sector Weight
1 Healthcare 41.55%
2 Consumer Discretionary 7.13%
3 Consumer Staples 5.35%
4 Technology 5.24%
5 Communication Services 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FEAM icon
151
5E Advanced Materials
FEAM
$56.5M
$2.69M 0.04%
+216,522
New +$4.1M
MTVA
152
MetaVia Inc
MTVA
$7.69M
$2.69M 0.04%
77,091
+13,743
+22% +$587K
PIII icon
153
P3 Health Partners
PIII
$33.8M
$2.57M 0.04%
133,000
-25,000
-16% -$655K
CHRN
154
ChronoScale Holdings
CHRN
$3.39B
$2.51M 0.04%
+144,467
New +$2.45M
MOBX icon
155
Mobix Labs
MOBX
$26.7M
$2.48M 0.04%
+233,600
New +$2.72M
ZGN icon
156
Zegna
ZGN
$4.08B
$2.38M 0.04%
242,000
+2,765
+1% +$28.6K
CMRX
157
DELISTED
Chimerix, Inc.
CMRX
$2.05M 0.03%
2,208,000
-16,000
-0.7% -$14.3K
VINC
158
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$1.94M 0.03%
135,200
+35,800
+36% +$491K
SRZN icon
159
Surrozen
SRZN
$255M
$1.67M 0.03%
139,000
-51,000
-27% -$450K
NKE icon
160
Nike
NKE
$63B
$1.59M 0.03%
+17,986
New +$1.41M
RNAC icon
161
Cartesian Therapeutics
RNAC
$245M
$1.59M 0.03%
+98,565
New +$1.54M
BCLI
162
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$1.59M 0.03%
459,844
-68,000
-13% -$321K
EVAX
163
Evaxion A/S
EVAX
$24.9M
$1.5M 0.02%
96,600
+18,200
+23% +$274K
ITRM
164
DELISTED
Iterum Therapeutics
ITRM
$1.46M 0.02%
+1,340,000
New +$1.59M
COSM icon
165
Cosmos Holdings
COSM
$13.3M
$1.45M 0.02%
+1,658,850
New +$1.88M
CANF
166
Can-Fite BioPharma American Depositary Shares
CANF
$6.86M
$1.31M 0.02%
32,500
+6,557
+25% +$351K
NKTR icon
167
Nektar Therapeutics
NKTR
$2.47B
$1.3M 0.02%
66,667
+10,934
+20% +$208K
WKSP icon
168
Worksport
WKSP
$11M
$1.28M 0.02%
299,300
+78,624
+36% +$491K
AIM
169
AIM ImmunoTech
AIM
$7.86M
$1.17M 0.02%
43,343
+2,522
+6% +$84.1K
AWH
170
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
$1.02M 0.02%
1,256,000
+788,000
+168% +$875K
MNST icon
171
Monster Beverage
MNST
$92.4B
$969K 0.02%
+18,568
New +$920K
GE icon
172
GE Aerospace
GE
$396B
$938K 0.02%
+4,974
New +$843K
ILMN icon
173
Illumina
ILMN
$30.2B
$930K 0.01%
+7,128
New +$879K
ARAY icon
174
Accuray
ARAY
$32.8M
$900K 0.01%
500,000
– –
PPBT
175
Purple Biotech
PPBT
$1.4M
$877K 0.01%
15,800
+9,010
+133% +$680K
5 6
7
8 9

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return
DSC
Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return
ACM
Altimeter Capital Management Boston, Massachusetts $5.7B AUM 36.74% 1-Year Est. Return
PI
PGGM Investments Zeist, Netherlands $5.7B AUM 17.05% 1-Year Est. Return

Armistice Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Armistice Capital held 331 positions worth $6.25B, down 21% from $7.95B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Armistice Capital withdrew a net $2.08B in Q3 2024, closing 73 positions and reducing 65 holdings. Its most notable exit was Exact Sciences, an estimated $59.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 33% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

Against the trend, Armistice Capital opened a new position in Paramount Global Class B worth $21.2M.

  • Armistice Capital's largest Q3 2024 buy was Paramount Global Class B: 2,000,000 shares worth $21.2M.
  • Armistice Capital added most to FIVE9 in Q3 2024, an estimated $41.6M increase.
  • Armistice Capital's biggest Q3 2024 reduction was Neurocrine Biosciences, cutting an estimated $109M.
  • Armistice Capital fully exited Exact Sciences in Q3 2024, selling an estimated $59.2M.
  • Armistice Capital's ten largest holdings make up 54% of its $6.25B portfolio in Q3 2024.
  • Armistice Capital opened 77 new positions and closed 73 in Q3 2024.
  • Armistice Capital's portfolio value fell 21% quarter-over-quarter to $6.25B.

Based on Armistice Capital's 13F filing for Q3 2024, filed 14 Nov 2024.